|
Recent news stories review the rationale of inhibiting Heat Shock Protein 90 (HSP90) in gastrointestinal stromal tumor and other cancers. There are a number of HSP90 inhibitors in current clinical trials for GIST (see our page under Emerging Treatments). Acess the news stories below for summaries of progress in this area. Drugs targeting the protein Hsp90 push already unstable cancer cells to the brink Infinity Scientist Lends Credibility To The Hsp90 Pursuit
Back
|
We subscribe to the HONcode principles. 
